Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

作者：Koh Won Jung; Lee Seung Heon; Kang Young Ae; Lee Chang Hoon; Choi Jae Chol; Lee Jae Ho; Jang Seung Hun; Yoo Kwang Ha; Jung Ki Hwan; Kim Ki Uk; Choi Sang Bong; Ryu Yon Ju; Kim Kyung Chan; Um Soojung; Kwon Yong Soo; Kim Yee Hyung; Choi Won Ii; Jeon Kyeongman; Hwang Yong Ii; Kim Se Joong; Lee Young Seok; Heo Eun Young; Lee Juhee; WoonKi Yeo; Shim Tae Sun; Yim Jae Joon^*

来源：American Journal of Respiratory and Critical Care Medicine, 2013, 188(7): 858-864.

DOI：10.1164/rccm.201303-0604OC

• multidrug-resistant tuberculosis
• fluoroquinolone
• moxifloxacin
• levofloxacin

Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. %26lt;br%26gt;Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. %26lt;br%26gt;Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. %26lt;br%26gt;Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). %26lt;br%26gt;Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).

• 出版日期2013-10-1